Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
about
Amyloid-β and Astrocytes Interplay in Amyloid-β Related DisordersTransnasal delivery of human A-beta peptides elicits impaired learning and memory performance in wild type mice.Temporal gene profiling of the 5XFAD transgenic mouse model highlights the importance of microglial activation in Alzheimer's disease.Acetylcholinesterase inhibitor modifications: a promising strategy to delay the progression of Alzheimer's disease.Increased fragmentation of sleep-wake cycles in the 5XFAD mouse model of Alzheimer's diseasePharmacological aspects of galantamine for the treatment of Alzheimer's disease.EFAD transgenic mice as a human APOE relevant preclinical model of Alzheimer's disease.Pharmacological, toxicological and neuronal localization assessment of galantamine/chitosan complex nanoparticles in rats: future potential contribution in Alzheimer's disease management.Nasal Application of the Galantamine Pro-drug Memogain Slows Down Plaque Deposition and Ameliorates Behavior in 5X Familial Alzheimer's Disease Mice.Limited Effects of Prolonged Environmental Enrichment on the Pathology of 5XFAD Mice.Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.Galantamine prevents long-lasting suppression of excitatory synaptic transmission in CA1 pyramidal neurons of soman-challenged guinea pigs.Role of Plant Derived Alkaloids and Their Mechanism in Neurodegenerative Disorders.
P2860
Q26766934-A259164B-5B92-4D6A-85EC-203E6947D8E6Q27315991-9505EF4B-4469-4069-B283-8D3C345013DEQ34545200-724C728C-0C31-4C61-92A1-0566122C2CE9Q35169922-4CC84FE3-D4EA-4264-BCF5-4B6665038DD0Q35182808-C97031A5-C428-4ECB-877E-8E661125973AQ37654613-6B843913-9737-4E82-8E72-8A6DD9BA4DF5Q38733357-FA0AE413-6370-4913-B8A9-C14661CC1B20Q38899961-BAFDAFA5-7468-4396-B53D-2884F12330D5Q39193474-7173301C-62CB-41AE-B50F-9BDAE3A70181Q39297069-B06C18D1-D686-4539-8271-6152B6CEFA99Q40777740-408565FA-B3EC-44C5-8223-5828CC055E3CQ46805223-FB65511B-D009-44A2-8FA4-B633CAAFC058Q55360003-C58BAB28-B380-4611-9F4F-F4BF849BC363
P2860
Galantamine slows down plaque formation and behavioral decline in the 5XFAD mouse model of Alzheimer's disease.
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Galantamine slows down plaque ...... e model of Alzheimer's disease
@nl
Galantamine slows down plaque ...... model of Alzheimer's disease.
@ast
Galantamine slows down plaque ...... model of Alzheimer's disease.
@en
type
label
Galantamine slows down plaque ...... e model of Alzheimer's disease
@nl
Galantamine slows down plaque ...... model of Alzheimer's disease.
@ast
Galantamine slows down plaque ...... model of Alzheimer's disease.
@en
prefLabel
Galantamine slows down plaque ...... e model of Alzheimer's disease
@nl
Galantamine slows down plaque ...... model of Alzheimer's disease.
@ast
Galantamine slows down plaque ...... model of Alzheimer's disease.
@en
P2093
P2860
P3181
P1433
P1476
Galantamine slows down plaque ...... model of Alzheimer's disease.
@en
P2093
Alfred Maelicke
Christin Haertel
Soumee Bhattacharya
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0089454
P407
P50
P577
2014-02-21T00:00:00Z